ABSTRACT Cells from the malignant teratocarcinoma line PCC4.azal were treated with the mutagen N-methyl-N-nitro-N-nitrosoguanidine. Fifty-five clones were isolated from the surviving cells. Twelve clones are unable to form tumors in the syngeneic 129/Sv mice. However, these "tum" clones form tumors as readily as the original cells when they are injected into irradiated mice. Moreover, they stimulate the production of immune memory cells, which protect the injected animals and confer resistance by adoptive transfer. The tum-clones are therefore unable to generate tumors in syngeneic mice because they elicit an immune rejection response.
A number of transplantable teratocarcinoma tumors have been obtained by Stevens in the inbred mouse strain 129/Sv (1). These progressive tumors contain a chaotic array of ectodermal, endodermal, and mesodermal differentiated tissues. The differentiated areas are separated by regions of undifferentiated, actively multiplying cells. These cells, which are called embryonal carcinoma cells, are malignant and pluripotent: the injection of a single embryonal carcinoma cell can result in the appearance of a tumor containing all the differentiated tissues found in teratomas (2) .
It is possible to put cells from ascitic teratocarcinomas in culture and to derive stable permanent cell lines from the embryonal carcinoma cells. Some of these lines are malignant and pluripotent (3) (4) (5) (6) (7) . The pluripotency suggests that there may be an equivalence between the cells present in early embryos and those of teratocarcinoma lines. Further support for this hypothesis comes from the finding that teratocarcinoma cells elicit in syngeneic mice an antibody response against the "F9" surface antigen, an antigen present on early embryos and absent on the differentiated tissues of adult mice with the exception of the germ line (8) . Moreover, like early embryo cells, teratocarcinoma pluripotent cells do not carry H-2 antigens (9, 10).
The work described below has been performed entirely with line PCC4.azal. This is an azaguanine-resistant clone derived from the permanent line PCC4 (6) . When PCC4.azal cells are injected into 129/Sv mice, they give rise to large progressive tumors in a few weeks. These tumors contain numerous regions of various differentiated tissues, as found in primary teratocarcinomas.
As a means of investigating the cell determination processes of early embryos, we thought that it would be useful to obtain a number of PCC4.azal variants that have lost some specific differentiation potentialities. We treated a culture of PCC4.azal with a mutagen. The surviving population was cloned and the properties of a number of clones were analyzed both in vitro and in vivo. This procedure has yielded a number of variants with a decreased differentiation potential. They have been briefly described elsewhere (11) .
In the course of this experiment, we noticed that a large number of the mutagen treated clones failed to produce progressive tumors in the syngeneic 129/Sv mice. Further experiments confirmed that these clones had a very much reduced tumorigenicity. We will describe here the isolation and initial characterization of these "tumorless" (tum-) variants. We will show that their inability to generate progressive tumors is not due to an intrinsic growth defect, but to the fact that they trigger an immune rejection response in the syngeneic host.
MATERIALS AND METHODS Mice. Mice from the inbred 129/Sv line were obtained from J. L. Guenet (Institut Pasteur, Paris). Unless otherwise mentioned, the mice were more than 7 and less than 12 weeks old.
Steel/+ and +/+ mice were used indifferently.
Teratocarcinoma Cell Lines. Line PCC4.azal is a clonal, permanent cell line resistant to a concentration of 15 /Ag of azaguanine per ml (5) . It was derived from line PCC4, which itself was derived from the transplantable teratocarcinoma OTT 6050 obtained by Stevens in 129/Sv mice (1). The isolation and cloning procedures of these lines have been fully described elsewhere (5). PCC4.azal and the clones described below were found to be free of mycoplasma.
Culture The immunized mice were injected with 2.106 living cells of a tumclone on day 0. On day 21, they were given 600 rads of gamma radiation and were injected 3-6 hr later with 2-106 living cells of the same tum-clone. The control mice were not injected on day 0. On day 21 they were irradiated and injected like the immunized mice. The results are pooled from a number of independent experiments.
were always obtained when the mice were irradiated any time between 7 days before and the time of injection. Irradiations performed after the day of injection had a decreasing effectiveness up to the fifth day. Later irradiation did not result in the formation of tumors. Cells from clone 25 can therefore survive 5 days in the animal even though they eventually fail to form a tumor.
Presence of radioresistant memory To test whether the rejection of the tum-cells is really due to an immune response, we took advantage of the fact that immune memory cells are often relatively radioresistant (12) .
Mice were injected with 2-106 cells of tum-variant 20. No tumors occurred, as expected. Three weeks later these "immunized" mice together with a group of control mice were given 600 rads of y radiation. All the mice were then injected with 2-106 cells of variant 20. None of the immunized mice acquired a tumor. All the control mice did. Experiments performed with tum-variants 25, 70, 42, and 133 gave the same results, as shown in Table 2 .
It appears therefore that the mice injected with a tumvariant acquire a radioresistant memory against this variant.
Protection of irradiated mice by adoptive transfer of immune spleen cells Mice were injected with 2-106 living cells of variant 25. Three weeks later, their spleen cells were collected and injected intravenously into irradiated animals. These "reconstituted" mice as well as irradiated, nonreconstituted control mice were injected 4 with a rather high frequency. These tum-variants are still able to form tumors in irradiated mice, indicating that they have kept the neoplastic properties of the original tum+ cells. However, they provoke a strong immune rejection process in the syngeneic 129/Sv mice. Nitrosoguanidine is a potent mutagen and the tum. phenotype is stable in culture. It is therefore tempting to consider that the tum-character is determined by a mutation on the chromosomal DNA. After mutagenesis, about 0.5% of the initial cells survive and this population contains about 20% tumvariants. Let us assume that all the killing as well as the production of tum-phenotypes is due to random dominant mutations induced by the drug. According to the law of Poisson, this implies that the genetic target governing the tum-phenotype amounts to four percent of the size of the genetic target governing cell multiplication in vitro. This surprisingly large relative value becomes even larger if nitrosoguanidine induces some nonspecific killing, not due to its mutagenic action.
Two questions arise immediately from the existence of tumvariants. First, what is the difference between a tum-cell and its tum+ equivalent? Second, what is the precise mechanism of rejection of the tum-cells?
The difference between a tum-cell and the corresponding tum+ could be either structural or functional. tum-variants may have acquired new surface antigens causing them to be rejected. Alternatively, they may have lost hypothetical functions whereby the tum+ cell either avoids stimulating an immune rejection response or becomes resistant to it. Some information regarding this should emerge from a systematic study of the cross-protection patterns existing between different tumvariants.
The mechanism of rejection of tumoral cells has been studied with various tests like those of lymphocyte cytotoxicity, cytostasis, stimulation of lymphocyte multiplication, and inhibition of macrophage migration (13) (14) (15) (16) 
